Rep. Gilbert Ray Cisneros Jr. (D-CA) Buys Alkermes (ALKS) Stock
Rep. Gilbert Ray Cisneros Jr. made a notable purchase of Alkermes shares on September 29, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Rep. Gilbert Ray Cisneros Jr. (D-CA) bought between $1,001 and $15,000 of Alkermes plc ($ALKS) stock on September 29, 2026. The trade was disclosed in a STOCK Act periodic transaction report filed October 12, 2026.
Since the trade, $ALKS is up 2.1% after 1 week and up 1.0% to date (from the $40.80 close on Sep 29, 2026).
Financial Disclosure Report
Clerk of the House of Representatives • Legislative Resource Center • B81 Cannon Building • Washington, DC 20515
Filer Information
- Name:
- Rep. Gilbert Ray Cisneros Jr. (D)
- Status:
- Member — House
- Party:
- Democrat
Filing Information
- Filing Type:
- Periodic Transaction Report
- Filing Year:
- 2026
- Filing Date:
- Oct 12, 2026
Schedule B: Transactions
| Asset | Transaction | Date | Amount |
|---|---|---|---|
| Alkermes plc ($ALKS) | Buy | Sep 29, 2026 | $1,001 - $15,000 |
Summary of the filed report, not the original document. View the original: STOCK Act disclosure (House Clerk)
ALKS
Alkermes plc
Key Points
- Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, bought shares of Alkermes valued between $1,001 and $15,000 on September 29, 2026.
- Alkermes recently traded around $40.00 as of October 16, 2026, with a revenue growth of 27.0% year-over-year.
- Cisneros Jr. has previously sold shares of other companies, including Workday and W. R. Berkley, on June 5, 2026.
Get $ALKS trade alerts by text
We text you when insiders, Congress or big funds trade $ALKS. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Alkermes plc alert may contain errors. Disclosures
Rep. Gilbert Ray Cisneros Jr., a Democrat from California's 31st district, bought shares of Alkermes plc (NasdaqGS: ALKS) valued between $1,001 and $15,000 on September 29, 2026. This transaction was disclosed in a periodic transaction report filed under the STOCK Act on October 12, 2026.
Gilbert Ray Cisneros Jr. vs. the S&P 500
Hypothetical returns from Gilbert Ray Cisneros Jr.'s disclosed trades, not real profit or advice. How we model this.
What Changed in Gilbert Ray Cisneros Jr.'s Alkermes Position
Cisneros Jr. initiated a new position in Alkermes by purchasing shares valued between $1,001 and $15,000. This marks a new investment for the lawmaker, reflecting his interest in the biopharmaceutical sector.
Other Institutional Activity in Alkermes
Several institutional investors have been active in Alkermes. Blackrock Inc. grew its holdings by 920,253 shares, ending with 29,235,739 shares worth about $1.21 billion. Vanguard Capital Management LLC added 87,643 shares, bringing its total to 7,515,025 shares valued at approximately $309.8 million. Meanwhile, State Street Corporation trimmed its stake by 304,785 shares, resulting in 9,160,575 shares worth around $377.6 million.
Alkermes plc Stock Down 7.8%
Alkermes shares recently traded around $40.00 as of October 16, 2026. The stock is performing well, with a revenue growth of 27.0% year-over-year. However, the shares have not yet reached their peak, as they are below prior highs.
Recent Earnings
Alkermes reported trailing twelve-month revenue of approximately $1.67 billion and an EPS of $0.38. The company has a net margin of 4.0% and a return on equity (ROE) of 3.9%. Alkermes is set to announce its next earnings on October 28, 2026.
Insider Buying and Selling at Alkermes plc
Recent insider transactions show that several officers of Alkermes have sold shares. David Joseph Gaffin sold 2,034 shares at an average price of $48.58 on August 3, 2026, totaling about $98,812. Christian Todd Nichols sold 7,576 shares on August 17, 2026, valued at approximately $372,937. Craig C. Hopkinson sold 9,000 shares at $46.99 on September 1, 2026, worth around $422,874. These sales indicate ongoing activity among insiders.
Analysts Set New Price Targets
On September 22, 2026, Baird maintained an Outperform rating on Alkermes with a new price target of $61.00, up from $58.00. Needham reiterated a Buy rating with a price target of $62.00 on September 21, 2026. The consensus among analysts remains positive, indicating confidence in Alkermes’ future performance.
About Alkermes plc
Alkermes plc is a biopharmaceutical company based in Dublin, Ireland. It focuses on developing and commercializing products for various medical needs, including treatments for opioid and alcohol dependence, as well as mental health conditions like schizophrenia and bipolar disorder. This recent purchase by Cisneros Jr. highlights a growing interest in the healthcare sector, particularly in companies addressing critical therapeutic areas.
Bottom Line
Investors should watch for Alkermes' upcoming earnings announcement on October 28, 2026, for insights into its financial health. As more lawmakers and institutional investors engage with the stock, it could signal broader trends in the healthcare market.
Related Filing Alerts
Source: Gilbert Ray Cisneros Jr.'s STOCK Act disclosure on $ALKS (Sep 29, 2026). Read the original filing: STOCK Act disclosure (House Clerk). Written by software, not financial advice. How we make alerts